Progress towards a dengue vaccine (Q35009119)

5 August 2017

1 reference

title

Progress towards a dengue vaccine (English)

1 reference

5 August 2017

0 references

1 reference

2

1 reference

5 August 2017

Daniel P Webster

1

1 reference

5 August 2017

Sarah Rowland-Jones

series ordinal

3

1 reference

5 August 2017

1 November 2009

1 reference

Lancet Infectious Diseases

5 August 2017

1 reference

5 August 2017

9

1 reference

5 August 2017

11

1 reference

5 August 2017

678-687

1 reference

on focus list of Wikimedia project

5 August 2017

ScienceSource

0 references

cites work

Global spread and persistence of dengue

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

The global emergence/resurgence of arboviral diseases as public health problems

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Epidemic dengue/dengue hemorrhagic fever as a public health, social and economic problem in the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Recent shift in age pattern of dengue hemorrhagic fever, Brazil

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Impact of dengue/dengue hemorrhagic fever on the developing world

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Invited commentary: Dengue lessons from Cuba

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Evolution of dengue virus type 2 during two consecutive outbreaks with an increase in severity in southern Taiwan in 2001-2002.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Spectrum of disease and relation to place of exposure among ill returned travelers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue fever, Hawaii, 2001-2002

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

From the World Health Organization. Development of dengue and Japanese encephalitis vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Developing vaccines against flavivirus diseases: past success, present hopes and future challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Early clinical and laboratory indicators of acute dengue illness

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

The WHO dengue classification and case definitions: time for a reassessment

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue in Vietnamese Infants—Results of Infection‐Enhancement Assays Correlate with Age‐Related Disease Epidemiology, and Cellular Immune Responses Correlate with Disease Severity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Nutritional status of children with dengue hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

The Emperor's New Clothes revisited, or reflections on the pathogenesis of dengue hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue hemorrhagic fever in Cuba, 1981: a retrospective seroepidemiologic study

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

HLA-DR antigen frequencies in Mexican patients with dengue virus infection: HLA-DR4 as a possible genetic resistance factor for dengue hemorrhagic fever.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Protective and Enhancing HLA Alleles, HLA-DRB1*0901 and HLA-A*24, for Severe Forms of Dengue Virus Infection, Dengue Hemorrhagic Fever and Dengue Shock Syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue hemorrhagic fever with special emphasis on immunopathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Research on dengue during World War II

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue virus-specific human T cell clones. Serotype crossreactive proliferation, interferon gamma production, and cytotoxic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue: defining protective versus pathologic immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Immunopathological mechanisms in dengue and dengue hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Immunopathogenesis of Dengue hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Towards a dengue vaccine: progress to date and remaining challenges

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Monoclonal antibody-mediated enhancement of dengue virus infection in vitro and in vivo and strategies for prevention

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Neutralizing antibodies after infection with dengue 1 virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue viremia titer, antibody response pattern, and virus serotype correlate with disease severity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue 4 virus monoclonal antibodies identify epitopes that mediate immune infection enhancement of dengue 2 viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

In Vivo Enhancement of Dengue Virus Infection in Rhesus Monkeys by Passively Transferred Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Activation of endothelial cells via antibody-enhanced dengue virus infection of peripheral blood monocytes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Release of vasoactive cytokines by antibody-enhanced dengue virus infection of a human mast cell/basophil line

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue virus selectively induces human mast cell chemokine production

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue virus (DENV) antibody-dependent enhancement of infection upregulates the production of anti-inflammatory cytokines, but suppresses anti-DENV free radical and pro-inflammatory cytokine production, in THP-1 cells

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dramatic caspase-dependent apoptosis in antibody-enhanced dengue virus infection of human mast cells.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

1 reference

7 January 2021

Risk factors and clinical features associated with severe dengue infection in adults and children during the 2001 epidemic in Chonburi, Thailand

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue Virus (DV) enhancing antibody activity in preillness plasma does not predict subsequent disease severity or viremia in secondary DV infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five- to twelve-year-old Thai children

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers: role of serotype concentration, ratio, and multiple doses.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax-DEN2) vaccine: Phase I clinical trial for safety and immunogenicity: effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

The Alexander D. Langmuir Lecture. The pathogenesis of dengue. Molecular epidemiology in infectious disease

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Of cascades and perfect storms: the immunopathogenesis of dengue haemorrhagic fever-dengue shock syndrome (DHF/DSS).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Delayed-type hypersensitivity: probable role in the pathogenesis of dengue hemorrhagic fever/dengue shock syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Understanding the contribution of cellular immunity to dengue disease pathogenesis

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

T cell responses in dengue hemorrhagic fever: are cross-reactive T cells suboptimal?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue virus-reactive CD8+ T cells display quantitative and qualitative differences in their response to variant epitopes of heterologous viral serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

High Pro-Inflammatory Cytokine Secretion and Loss of High Avidity Cross-Reactive Cytotoxic T-Cells during the Course of Secondary Dengue Virus Infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Preservation of a critical epitope core region is associated with the high degree of flaviviral cross-reactivity exhibited by a dengue-specific CD4+ T cell clone

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Increased frequencies of CD4+ CD25(high) regulatory T cells in acute dengue infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

IL-10 levels in Dengue patients: some findings from the exceptional epidemiological conditions in Cuba

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Pathogenesis of dengue: challenges to molecular biology

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Understanding respiratory syncytial virus (RSV) vaccine-enhanced disease.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Immunological serotype interactions and their effect on the epidemiological pattern of dengue.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

"Guidelines for the clinical evaluation of dengue vaccines in endemic areas": summary of a World Health Organization Technical Consultation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Yellow fever vaccine induces integrated multilineage and polyfunctional immune responses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Cell-mediated immunity induced by chimeric tetravalent dengue vaccine in naive or flavivirus-primed subjects

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Progress in development of a live-attenuated, tetravalent dengue virus vaccine by the United States Army Medical Research and Materiel Command.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Live attenuated tetravalent dengue vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

rDEN4delta30, a live attenuated dengue virus type 4 vaccine candidate, is safe, immunogenic, and highly infectious in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3′ untranslated region (3′-UTR) or by exchange of the DENV-3 3′-UTR with that of DENV-4

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

rDEN2/4Delta30(ME), a live attenuated chimeric dengue serotype 2 vaccine is safe and highly immunogenic in healthy dengue-naïve adults.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

An evaluation of dengue type-2 inactivated, recombinant subunit, and live-attenuated vaccine candidates in the rhesus macaque model

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Construction and Characterization of a Single-Cycle Chimeric Flavivirus Vaccine Candidate That Protects Mice against Lethal Challenge with Dengue Virus Type 2

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

A novel dengue vaccine candidate that induces cross-neutralizing antibodies and memory immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

A DNA vaccine candidate expressing dengue-3 virus prM and E proteins elicits neutralizing antibodies and protects mice against lethal challenge

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

A DNA vaccine expressing dengue type 2 virus premembrane and envelope genes induces neutralizing antibody and memory B cells in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Evaluation of immunity and protective efficacy of a dengue-3 pre-membrane and envelope DNA vaccine in Aotus nancymae monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

A Tetravalent Dengue Vaccine Based on a Complex Adenovirus Vector Provides Significant Protection in Rhesus Monkeys against All Four Serotypes of Dengue Virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Pediatric Measles Vaccine Expressing a Dengue Antigen Induces Durable Serotype-specific Neutralizing Antibodies to Dengue Virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Dengue vaccines approach the finish line

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Antibody to dengue 1 detected more than 60 years after infection

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Development of a live attenuated dengue virus vaccine using reverse genetics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Safety and immunogenicity of attenuated dengue virus vaccines (Aventis Pasteur) in human volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Introduction of mutations into the non-structural genes or 3' untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Third-generation flavivirus vaccines based on single-cycle, encapsidation-defective viruses

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Toll or toll-free adjuvant path toward the optimal vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Heterologous protection against influenza by injection of DNA encoding a viral protein

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Induction of antigen-specific cytotoxic T lymphocytes in humans by a malaria DNA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Induction of CD4(+) T cell-dependent CD8(+) type 1 responses in humans by a malaria DNA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Induction of CD8+ T cells using heterologous prime-boost immunisation strategies

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Safety and immunogenicity of NYVAC-JEV and ALVAC-JEV attenuated recombinant Japanese encephalitis virus--poxvirus vaccines in vaccinia-nonimmune and vaccinia-immune humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Adenovirus-based vaccines generate cytotoxic T lymphocytes to epitopes of NS1 from dengue virus that are present in all major serotypes

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

Recombinant vector derived from live attenuated measles virus: potential for flavivirus vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2809%2970254-3

7 January 2021

10.1016/S1473-3099(09)70254-3

Identifiers

DOI

1 reference

release_ldd7h3aefrgfph75w5zteldgzq

5 August 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/ldd7h3aefrgfph75w5zteldgzq

24 November 2022

mapped directly with Wikidata item

1 reference